AstraZeneca Immunotherapy Drug Earns FDA Approval
- Posted by ISPE Boston
- On February 21, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the FDA has approved Imfinzi for the treatment of certain patients with non-small cell lung cancer (NSCLC), specifically those with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Stage III (locally advanced) NSCLC is […]
Read More